- Home
- AXSM vs PSO Comparison
AXSM vs PSO Comparison
Compare AXSM & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | PSO |
|---|---|---|
| Founded | 2012 | 1844 |
| Country | United States | United Kingdom |
| Employees | N/A | 17116 |
| Industry | Biotechnology: Pharmaceutical Preparations | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.2B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AXSM | PSO |
|---|---|---|
| Price | $159.55 | $13.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $209.18 | N/A |
| AVG Volume (30 Days) | 468.7K | ★ 996.0K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ 38.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.34 | $5.90 |
| Revenue Next Year | $54.30 | $4.88 |
| P/E Ratio | ★ N/A | $14.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $86.99 | $12.02 |
| 52 Week High | $191.50 | $16.70 |
Technical Indicators
Market Signals| Indicator | AXSM | PSO |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 57.27 |
| Support Level | $148.14 | $12.92 |
| Resistance Level | $191.13 | $13.34 |
| Average True Range (ATR) | 5.42 | 0.22 |
| MACD | -1.09 | 0.07 |
| Stochastic Oscillator | 4.78 | 82.74 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About PSO Pearson Plc
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.